LiveSaturday · 14 November 2026Vol. VIII · No. 318
Bangalore
20°C · Partly cloudy20°C
Sat, 14 Nov
Latest
Politics

Comply with new prices of 137 anti-cancer drugs or face action, says regulator

NPPA orders strict compliance with revised prices for 137 anti-cancer drugs, warns penalties for violations, and directs monitoring across the pharma supply chain.

Comply with new prices of 137 anti-cancer drugs or face action, says regulator

NPPA directs State drug controllers to strictly monitor prices

Published - November 14, 2026 01:24 am IST - NEW DELHI

The revised prices for the 137 anti-cancer drugs came into effect on November 9, 2026, following a gazette order issued on October 17, 2026. The order capped the trade margin on these medicines at 30%. File image used for representation | Photo Credit: Getty Images/iStockphoto

The National Pharmaceutical Pricing Authority (NPPA) has warned of penal action against those failing to comply with the revised prices of 137 non-scheduled anti-cancer drugs

The authority, which functions under the Department of Pharmaceuticals, has asked State drug controllers (SDCs) to strictly monitor the prices and submit their action taken reports by November 16, according to an official release on Friday (November 13, 2026).

The revised prices for the 137 anti-cancer drugs came into effect on November 9, 2026, following a gazette order issued on October 17, 2026. The order capped the trade margin on these medicines at 30%.

Based on submissions received from pharmaceutical companies up to November 11, the latest revised price lists have been uploaded on the NPPA website as well as the Pharma Sahi Daam app and portal, the Chemicals and Fertilizers Ministry said.

All manufacturers, stockists, dealers, retailers, hospitals, and medical institutions have been directed to comply with the revised prices and prominently display the updated price lists at their premises and on their websites.

The SDCs have been instructed to strictly monitor compliance across the supply chain and healthcare facilities to ensure that the benefits of the revised maximum retail prices (MRPs) are passed on to patients.

Any violation of the directive may attract overcharging proceedings under the provisions of the DPCO, 2013, the release noted.

Complaints regarding overcharging, shortage, or non-availability of medicines can be reported through the Pharma Sahi Daam app or portal, the NPPA helpline (1800-111-255), or via email at monitoring-nppa@gov.in, it added.

Published - November 14, 2026 01:24 am IST

cancer / disease / medicine / health / Drugs / law

Terms & conditions | Institutional Subscriber

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.

Related in Politics

Latest Across Vijaya Chronicle